title: Leishmaniasis impact and treatment access.
abstract: According to disease burden estimates, leishmaniasis ranks third in disease burden in disability-adjusted life years caused by neglected tropical diseases and is the second cause of parasite-related deaths after malaria; but for a variety of reasons, it is not receiving the attention that would be justified seeing its importance. This is especially apparent in the unnecessarily and unacceptably poor access to timely and appropriate treatment for patients. To our knowledge, this is the first publication that addresses the major issues associated with poor access to drugs for leishmaniasis and that outlines a number of feasible and practical solutions.
authors.affiliation: Leishmaniasis Control Programme, WHO/IDM. Av. Appia, Geneva, Switzerland.
authors.forename: M
authors.initials: M
authors.lastname: den Boer
authors.forename: D
authors.initials: D
authors.lastname: Argaw
authors.forename: J
authors.initials: J
authors.lastname: Jannin
authors.forename: J
authors.initials: J
authors.lastname: Alvar
mesh_terms: D000981:Antiprotozoal Agents / Q000191:economics* / Q000627:therapeutic use; D060085:Coinfection / Q000191:economics / Q000469:parasitology; D017281:Cost of Illness; D003695:Delivery of Health Care / Q000191:economics* / Q000331:legislation & jurisprudence; D016527:Drug Costs / Q000331:legislation & jurisprudence / Q000592:standards; D019353:Endemic Diseases / Q000191:economics; D005843:Geography; D014943:Global Health / Q000191:economics; D006801:Humans; D007891:Leishmania / Q000472:pathogenicity; D007896:Leishmaniasis / Q000191:economics / Q000453:epidemiology / Q000628:therapy* / Q000635:transmission; D011203:Poverty / Q000191:economics
chemical_list: D000981:Antiprotozoal Agents